Montreal
Green Cross Biotherapeutics began building a $256 million biopharmaceutical manufacturing facility in Canada in June of 2015. Located on the Montreal Technoparc's Saint-Laurent Campus, the project will support the production of intravenous immunoglobulin (IVIG) and albumin products, and will act as the company's North American headquarters. The 225,000-gsf facility is expected to be fully operational in 2019 and will accommodate 200 scientists, engineers, and support staff. Green Cross Biotherapeutics is headquartered Yongin, South Korea.
Source
